Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
HIV/AIDS
•
Rheumatology
•
Rheumatoid Arthritis
•
Infectious Disease
•
Immunosuppression
What is your approach for managing DMARDs in patients with rheumatoid arthritis and newly diagnosed HIV?
Related Questions
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How do you approach restarting cDMARDS/bDMARDS in a patient with active RA after incidence of disseminated CNS VZV infection while on tofacitinib?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
Is it ever safe to use a biologic DMARD in a patient with RA who is on suppressive antibiotics due to a history of septic prosthetic arthritis?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Would you uptitrate methotrexate dosing when a patient flares on a TNFi and methotrexate 15 mg weekly?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Do you combine methotrexate and leflunomide for the treatment of RA?
